A View LCS vs Tempus ECG-AF
AI Verdict
Choose AVIEW LCS if…
Choose A View LCS if your primary goal is a comprehensive, multi-faceted assessment of thoracic health from a single low-dose CT scan. This tool is ideal for lung cancer screening programs that also require quantification of emphysema and coronary artery calcification, streamlining the diagnostic workflow and generating automated reports for multiple conditions.
View AVIEW LCS →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to proactively identify older patients (65+) at an elevated risk of developing new-onset atrial fibrillation within the next year, using standard 12-lead ECGs. This tool is best suited for integrating into cardiology or internal medicine practices to support earlier intervention and follow-up for at-risk individuals without pre-existing AF.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | Tempus ECG-AF |
|---|---|---|
| Pricing | Subscription or one-off payment | Contact vendor |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSTool A emphasizes automated report generation, Lung-RADS scoring, and comprehensive analysis, which streamlines the workflow for radiologists. Its flexible deployment options (cloud, hybrid, local, virtualized) also enhance usability by accommodating diverse IT environments.
Clinical Value
AVIEW LCSTool A offers a broader range of diagnostic capabilities from a single low-dose CT scan, addressing multiple significant thoracic conditions like lung cancer, emphysema, and coronary artery calcification. This comprehensive approach provides higher overall clinical utility and efficiency compared to Tool B's more focused risk prediction.
Pricing & Value
Tempus ECG-AFTool B explicitly details CMS reimbursement availability with specific CPT codes and a Medicare rate, providing clear financial transparency and a pathway for adoption. Tool A only states 'contact for quote,' offering no immediate insight into its financial value proposition.
Enterprise Readiness
AVIEW LCSBoth tools meet essential regulatory and compliance standards (FDA, HIPAA, BAA). However, Tool A offers more flexible deployment options, including cloud, hybrid, local, and virtualized solutions, which caters to a wider range of enterprise IT infrastructures and security policies.
Innovation
Tempus ECG-AFWhile both leverage AI, Tool B's ability to predict the risk of new-onset Atrial Fibrillation within 12 months from a standard 12-lead ECG, trained on over 1.5 million ECGs, represents a significant advancement in proactive cardiac care and early intervention.
Support & Docs
Tempus ECG-AFTool B explicitly provides direct contact information for its cardiology support team via email and phone, indicating clear and accessible support channels. In contrast, while Tool A has technical documentation, explicit customer support contact details were not readily available in the provided information or web search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | Tempus ECG-AF |
|---|---|---|
| Name | A View LCS | Tempus ECG-AF |
| Company | Coreline Soft Co. | Tempus AI, Inc. |
| Primary Function | AI-powered medical imaging platform for comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. | AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Key Modality/Input Data | Thoracic CT scans (low-dose CT) | 12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems) |
| Target Condition/Disease | Lung cancer, Emphysema, Coronary Artery Calcification | Atrial Fibrillation/flutter (AF) risk prediction |
| Target Patient Population | Not specified | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and Tempus ECG-AF.